By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists generally agreed that both ABBV and JNJ are overvalued and carry significant risks, with ABBV's reliance on immunology pipeline success and JNJ's litigation and regulatory risks being major concerns.
Risk: ABBV's reliance on immunology pipeline success and JNJ's litigation and regulatory risks
Opportunity: None explicitly stated
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Dividend Kings are companies that have increased their dividends for 50 or more years in a row. If you're thinking of investing in one, you might be considering AbbVie (NYSE: ABBV) or Johnson & Johnson (NYSE: JNJ) stock. There are good reasons to invest in either -- or both -- and good reasons to favor dividend-paying stocks.
Here's a quick look at the two companies.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie is a pharmaceutical giant with a recent market value of $258 billion and a recent dividend yield of 2.7%. It boasts a deep pipeline, with about 90 treatments in development, some 60 of which are in mid- or late stages. It's exploring a promising weight-loss formulation, too.
The company recently inked a deal to buy Apogee Therapeutics for $10.9 billion. That will bring the promising eczema drug zumilokibart under AbbVie's roof, boosting its immunology portfolio.
AbbVie's stock has averaged annual gains of 17% over the past decade. Its stock seems a bit overvalued at recent levels, with a forward-looking price-to-earnings (P/E) ratio of 18, above its five-year average of 13.
Johnson & Johnson, having spun off its consumer products division (including brands such as Tylenol), is now a robust business focused on pharmaceuticals and medical devices. Indeed, J&J boasts 28 products or platforms that each generate at least $1 billion per year.
Its second-quarter report was strong, with revenue growing 6.6% year over year to $25 billion. The stock has averaged annual gains of 9% over the past decade, lower than AbbVie's returns. J&J's stock also seems overvalued at recent levels, arguably a little more so than AbbVie's. Its recent forward P/E of 22 is well above its five-year average of 16. The dividend recently yielded 2.1%.
Neither stock seems bargain-priced at recent levels. But I think AbbVie looks a bit more enticing based on valuation metrics, and it sports a fatter dividend yield.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $377,990! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,269,518!
Now, it’s worth noting Stock Advisor’s total average return is 896% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 26, 2026. *
Selena Maranjian has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"ABBV appears incrementally better on yield and growth optics, but both stocks are expensive relative to history and the article downplays ABBV's concentrated patent-risk exposure versus JNJ's broader platform stability."
The article positions ABBV as the better Dividend King buy versus JNJ on valuation (18x vs 22x forward P/E), higher 2.7% yield, stronger 17% annualized returns, and immunology pipeline momentum including the $10.9B Apogee deal. Both trade above historical averages, yet the piece leans ABBV while admitting neither is cheap. This feels like classic Motley Fool funneling toward their Stock Advisor upsell. Missing context: ABBV's heavy Humira cliff exposure (still ~30% of revenue) and upcoming patent expirations on key drugs, while JNJ offers greater diversification across 28 $1B+ platforms and more stable medical-device cash flows. ABBV's growth looks sexier but carries higher execution and litigation risk.
If weight-loss pipeline or zumilokibart fails to offset Humira erosion, ABBV's seemingly attractive 18x multiple could quickly re-rate to 13x or lower, erasing the valuation edge the article touts.
"Both companies are currently priced for perfection, masking the risks associated with their reliance on aggressive M&A to replace maturing drug patents."
The article focuses on dividend history, but misses the structural shifts in both firms. ABBV is navigating the post-Humira cliff, relying heavily on Skyrizi and Rinvoq to fill the revenue gap, while JNJ is now a pure-play medtech and pharma entity post-Kenvue spinoff. At a 18x forward P/E, ABBV is pricing in significant execution success in immunology and oncology. JNJ’s 22x forward P/E reflects a 'defensive' premium that may be unwarranted given ongoing talc litigation overhangs. Both are essentially bond proxies in the current rate environment. Investors should look past the 'Dividend King' label and focus on the R&D efficiency ratios, as both companies are paying high multiples for growth via M&A rather than organic pipeline success.
The 'overvaluation' narrative ignores that in a volatile market, the cash-flow stability and AAA-rated balance sheet of JNJ provide a risk-adjusted return profile that P/E ratios fail to capture.
"Both stocks are overvalued on absolute terms, but ABBV's lower multiple masks higher execution risk; neither warrants purchase until growth or M&A catalysts materialize or multiples compress 15-20%."
This article is thin on actual analysis. Both stocks trade at significant multiples above their 5-year averages (ABBV 18x vs. 13x; JNJ 22x vs. 16x), yet the author calls ABBV 'a bit more enticing' based solely on valuation and yield—ignoring that JNJ's 37.5% P/E premium might reflect legitimate structural advantages: 28 billion-dollar franchises vs. pipeline hope, lower execution risk, and post-spinoff focus. The Apogee deal ($10.9B for zumilokibart) is real, but eczema is a crowded market. Most critically: neither company's growth justifies current valuations without major pipeline wins or M&A accretion materializing. The article punts on patent cliffs, biosimilar pressure, and GLP-1 competition eating into legacy franchises.
If JNJ's 28 established billion-dollar franchises command a valuation premium over ABBV's pipeline-dependent model, that premium may be deserved and sustainable—meaning ABBV's 'cheaper' multiple reflects genuine risk, not opportunity.
"The article understates near-term Humira biosimilar risk and overstates valuation comfort, making current levels riskier than they appear."
The piece frames AbbVie and Johnson & Johnson as solid dividend plays with upside, but it glosses critical risk angles: AbbVie’s Humira-dominated revenue is facing accelerated biosimilar competition, which could erode near- to mid-term cash flow and complicate earnings growth even after Apogee. Debt and integration risk from M&A add to the caution. J&J’s premium multiple hinges on a broad mix of drugs, devices, and vaccines, yet litigation liabilities and regulatory risks keep a safety margin thin if growth disappoints. The article also omits macro-driven multiple compression risks and potential pricing pressures in pharma that could temper even steady growers.
Bull case against neutral: AbbVie could surprise on cash flow if biosimilar erosion slows and Apogee delivers, while J&J’s diversified portfolio might shield the downside and justify a high multiple.
"JNJ's premium is more fragile than Claude admits once medtech cyclicality and GLP-1 substitution risks are modeled."
Claude's claim that JNJ's 28 franchises justify a permanent 37.5% P/E premium ignores the post-Kenvue reality: medtech now dominates cash flows yet faces GLP-1 headwinds in obesity-adjacent devices and pricing pressure. ABBV's immunology concentration carries execution risk, but its 17% historical returns and Apogee pipeline give clearer near-term catalysts than JNJ's 'stable' but slower-growth profile.
"ABBV’s growth strategy carries higher systemic risk than JNJ’s diversified medtech-heavy model, justifying JNJ's valuation premium."
Grok, your focus on ABBV’s 'clearer catalysts' ignores the massive R&D failure rate inherent in the immunology space. You are betting on the Apogee pipeline, but JNJ’s medtech division isn't just 'slower growth'—it’s a hedge against the very binary clinical trial outcomes that could crater ABBV. By dismissing JNJ’s premium as unjustified, you’re ignoring the cost of capital. In a high-rate environment, ABBV’s reliance on M&A-fueled growth is far more fragile than JNJ’s organic cash-flow machine.
"JNJ's medtech division carries its own binary risks that don't justify a permanent valuation premium over ABBV's pipeline, only a different risk profile."
Gemini's R&D failure rate point is valid, but overstates JNJ's insulation. Medtech cash flows face their own binary risks—regulatory setbacks, reimbursement cuts, GLP-1 cannibalization of devices. ABBV's M&A fragility is real, but JNJ's 'organic machine' isn't immune to macro headwinds. Neither firm's multiple survives a 2-3% earnings miss. The real question: which binary outcome is priced in more harshly? ABBV's downside assumes Apogee fails; JNJ's assumes medtech holds. Both are baked in.
"ABBV's Apogee binary risk is underpriced in valuation; a delay or failure would re-rate ABBV, making JNJ's premium more defensible."
Responding to Claude: ABBV carries a binary Apogee risk that your 28 franchises argument glosses over. Even with Skyrizi and Rinvoq, Humira erosion and biosimilar timing could delay material growth and compress margins. If Apogee underperforms or delays, ABBV could re-rate toward the low-teens P/E, while JNJ's diversified, cash-flow-heavy model remains comparatively robust. The market may be pricing ABBV upside without fully pricing the downside risk.
The panelists generally agreed that both ABBV and JNJ are overvalued and carry significant risks, with ABBV's reliance on immunology pipeline success and JNJ's litigation and regulatory risks being major concerns.
None explicitly stated
ABBV's reliance on immunology pipeline success and JNJ's litigation and regulatory risks